BioSpace News Archive

NS Pharma, Inc. announces a webcast during the PPMD 2021 Virtual Annual Conference held from June 23 to 26 .

GT Biopharma, Inc.today announced that Dr. Jeffrey S. Miller will be giving an update on the progress of the GTB-3550 TriKE™ Phase I trial accompanying the Company’s corporate update presentation at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.

Epredia, and Aiforia, have announced today that they have entered into a commercial distribution agreement for Aiforia’s comprehensive portfolio of workflow enhancing solutions which enable pathologists to harness the power of deep learning AI for image analysis.

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today that a new peer-reviewed study published in Pain and Therapy demonstrates the efficacy of Nerivio® in treating menstrual migraine.

Boston IVF, a leading fertility clinic with more than 25 locations across the U.S., announced that it has partnered with TMRW Life Sciences, Inc. to bring unprecedented technology and automation to its cryostorage and fertility cell management practices.

Virpax ® Pharmaceuticals, Inc. today announced that the Investigational New Drug (IND) Application enabling studies for Envelta™ will also be used as a source for INDs for two additional indications for cancer pain.

Agitation and delirium are common occurrences in patients in intensive care units. The associated symptoms are marked by acute cerebral insufficiency arising out of structural and/or physiological abnormalities.

Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced new data in nine accepted abstracts to be presented at EASL International Liver Congress™ 2021 on June 23 – 26.

NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, announces that the Company’s proprietary intravenous cysteamine bitartrate therapy candidate is included in a global Phase 3 clinical trial being conducted and funded as part of REMAP-CAP.

Tarsus Pharmaceuticals, Inc. announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase 2b/3 Saturn-1 trial evaluating the company’s novel investigational therapeutic, TP-03, in patients with Demodex blepharitis.